Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company’s Board of Directors BOSTON and LONDON, ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

About Akari Therapeutics Akari Therapeutics is a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC ... Unlike current ADCs that use tubulin ...

The intrinsic factor of cell senescence, PCBP2, was identified by unlabeled quantitative proteomics, and its biological role in in vitro replication senescence of human bone marrow mesenchymal stromal ...

Other big financings this week Swiss biotech Alentis Therapeutics raised more than $181 million in a Series D that will support clinical trials of two antibody-drug conjugates (ADCs) targeting ...

Procentriole lengths are indicated in each image (um). Cyan: Acetylated tubulin; Magenta: Tedc1 (localized with anti-Flag antibody). Confocal image stacks were deconvolved using Microvolution; single ...

Antibody and Hoechst details are listed on Supplementary Table ... cells was analyzed by immunofluorescence staining of α- and γ-tubulin. We did not find any clear synergism in the four combinations ...